J&J Has Competition in the Race for the New Anti-Viagra

As Ed at Pharmalot noted recently, Vectura, a drug developer based in the UK, is boasting about a potential breakthrough for treating premature ejaculation, the frustrating sexual dysfunction which supposedly affects 30 per cent of men at some time in their life.

This news will be of interest to folks at J&J, who've been developing an anti-"I'm so sorry, I'm not normally like this" drug for some time. It's called dapoxetine.

The logic behind developing these drugs is obvious: Viagra was a huge success, it proved that men can be persuaded to ask their doctors for cures for even the most embarrasing problems. Thus we should repeat that success with a different but related condition.

Here's my prediction*: These drugs will be a flop. There's a big difference between not being able to perform at all, and being able to perform but not very well. Men will seek treatment for the former, not the latter. Also, ED is associated with age while PE is not. Without a clinical demographic to target, marketing this drug will be tough.

Regardless: Be on the lookout for clinical data inventing, er, or rather supporting, the notion that PE is some sort of clinical condition requiring treatment.

* I am willing to be wrong on this -- and will happily apologize if the evidence warrants it.

Comments

[[redacted by BWNRX]]

[redacted by BWNRX]

[アニメ抱き枕]

The logic behind developing these drugs is obvious: Viagra was a huge success, it proved that men can be persuaded to ask their doctors for cures for even the most embarrasing problems. Thus we should repeat that success with a different but related condition.